Welcome to our dedicated page for Globus Med SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Globus Medical, Inc. (NYSE: GMED) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a publicly traded musculoskeletal medical device manufacturer, Globus Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its operations, risk factors, financial performance, and material events.
Recent Form 8-K filings from Globus Medical have reported preliminary and final net sales and operating results for specific quarters and fiscal years, leadership transitions at the President, Chief Executive Officer, and Chief Financial Officer roles, and other significant corporate developments. These filings often reference earnings press releases furnished as exhibits, which include details on worldwide net sales, U.S. and international performance, non-GAAP financial measures, and guidance for future periods.
Through its filings, Globus Medical also explains its use of non-GAAP metrics such as non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow, constant currency net sales growth, and base business sales excluding contributions from recent acquisitions like Nevro Corp. and its subsidiaries. The company describes how these measures adjust for items such as litigation provisions, amortization of intangibles, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, and specific tax effects.
On this page, Stock Titan pairs Globus Medical’s raw SEC documents with AI-powered summaries that highlight the key points of lengthy filings. Users can quickly see what changed in a new 10-K or 10-Q, how management characterizes performance in 8-K earnings releases, and where non-GAAP adjustments have a material impact. The platform also surfaces real-time updates from EDGAR, helping investors follow new filings as they are posted and review the company’s regulatory history in one place.
Globus Medical (GMED) reported a director’s open‑market sales of Class A common stock. On 11/07/2025, the director sold 8,000 shares at $81, and on 11/10/2025 sold 2,000 shares at $85. These transactions were made under a Rule 10b5‑1 trading plan dated November 8, 2024. Following the reported trades, the director beneficially owned 15,384 shares.
Globus Medical (GMED) filed a Form 144 notice for a proposed sale of 8,000 common shares, with an aggregate market value of $647,681. The filing lists Raymond James & Associates as broker and indicates an approximate sale date of 11/07/2025 on the NYSE. Company shares outstanding are reported at 133,839,166.
The shares to be sold trace to a stock option exercise on 09/13/2024 for 20,000 shares, paid in cash. The notice also reports a recent transaction: Ann Rhoads sold 10,000 shares on 09/15/2025 for $584,000 in gross proceeds. Form 144 is a notice of intent and does not itself execute a sale; actual sales, if any, follow applicable Rule 144 conditions.
Globus Medical (GMED) reported strong Q3 2025 results. Net sales were $769.0 million versus $625.7 million a year ago, and operating income rose to $137.4 million from $48.1 million. Net income was $119.0 million with diluted EPS of $0.88, up from $0.38. For the first nine months, net sales reached $2.11 billion and net income was $397.3 million, which includes a bargain purchase gain tied to the Nevro transaction.
The company completed the Nevro acquisition on April 3, 2025 for total purchase price of $252.5 million and recorded a bargain purchase gain of $114.4 million year‑to‑date. Musculoskeletal Solutions drove Q3 with $741.0 million in sales, while Enabling Technologies contributed $28.0 million.
Globus ended the quarter with cash and cash equivalents of $371.8 million. Year‑to‑date operating cash flow was $504.9 million. Financing uses included repayment of senior convertible notes of $450.0 million and common stock repurchases of $255.5 million. Inventories were $771.5 million. Shares outstanding were 133,839,166 as of November 3, 2025; this is a baseline figure, not the amount being offered.
Globus Medical (GMED) filed an 8-K stating it issued a press release reporting sales and operating results for the three- and nine-month periods ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information under Item 2.02 and the related exhibit are “furnished” and not “filed” for purposes of Section 18 of the Exchange Act.
Director Ann D. Rhoads reported the sale of 10,000 shares of Class A Common Stock of Globus Medical, Inc. (GMED) on 09/15/2025 under a pre-established Rule 10b5-1 trading plan dated November 8, 2024. The weighted-average sale price was $58.46, with individual trade prices ranging from $58.22 to $58.81. After the reported dispositions, the reporting person beneficially owned 25,384 shares, held directly. The Form 4 was executed by an attorney-in-fact on behalf of the reporting person.
Form 144 notice for Globus Medical, Inc. (GMED) reports a proposed sale of 10,000 shares of common stock through Raymond James & Associates on the NYSE with an approximate aggregate market value of $584,000. The filer shows the securities were acquired and are to be sold on 09/15/2025 pursuant to a cashless stock option, with payment and acquisition both recorded on that date. The filing lists 98,254,456 shares outstanding for the issuer. The filer attests they do not possess undisclosed material adverse information and includes the standard Rule 10b5-1/trading-plan notice language.
Keith W. Pfeil, identified as President, CEO and a director of Globus Medical (GMED), received a grant of 40,000 stock options on 07/18/2025 with an exercise price of $56.34. The options are exercisable into 40,000 shares of Class A common stock and are held directly. Vesting begins on 07/18/2025 and occurs over four years: one-fourth vests on 07/18/2026 and the remainder vests ratably monthly over the following 36 months. The form reports the grant as an acquisition (A) of derivative securities (stock options).
Kyle Kline, Senior Vice President and Chief Financial Officer of Globus Medical (GMED), received an award of stock options on 07/18/2025. The grant totals 20,909 stock options to purchase Class A common stock at an exercise price of $56.34 per share. The options vest over four years with one-quarter vesting on the first anniversary of the vesting commencement date (07/18/2026) and the remainder vesting ratably each month over the following 36 months. The options expire on 07/18/2035 and are reported as directly beneficially owned following the transaction.
Kyle Kline, identified as Senior Vice President, Chief Financial Officer, filed an initial Form 3 reporting derivative holdings in Globus Medical, Inc. (GMED) related to stock options. The report, for an event dated 07/18/2025, lists seven option grants exercisable on dates from 01/25/2031 through 01/30/2035 covering a total of 51,591 underlying shares of Class A common stock. Strike prices on the grants range from $51.87 to $93.12, and each grant is reported as held directly. No non-derivative (direct) shares of common stock are reported on Table I. The filing is signed by an attorney-in-fact on behalf of the reporting person.